A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Incyte Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 70,100 shares of INCY stock, worth $4.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70,100
Previous 90,700 22.71%
Holding current value
$4.04 Million
Previous $5.7 Million 29.89%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$56.55 - $66.59 $1.94 Million - $2.28 Million
-34,312 Reduced 10.35%
297,250 $16.9 Million
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $4.4 Million - $5.42 Million
-84,428 Reduced 20.3%
331,562 $20.8 Million
Q3 2023

Nov 14, 2023

SELL
$57.77 - $65.93 $81.5 Million - $93.1 Million
-1,411,423 Reduced 77.24%
415,990 $24 Million
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $109 Million - $135 Million
1,793,088 Added 5223.85%
1,827,413 $114 Million
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $2.18 Million - $2.67 Million
31,083 Added 958.76%
34,325 $2.48 Million
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $2.74 Million - $3.43 Million
-40,724 Reduced 92.63%
3,242 $260,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $2.62 Million - $3.28 Million
39,643 Added 917.03%
43,966 $2.93 Million
Q2 2022

Aug 15, 2022

SELL
$66.18 - $83.18 $73.2 Million - $92 Million
-1,106,259 Reduced 99.61%
4,323 $328,000
Q1 2022

May 16, 2022

BUY
$66.02 - $79.71 $16.9 Million - $20.4 Million
255,786 Added 29.92%
1,110,582 $88.2 Million
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $25.4 Million - $29.7 Million
400,346 Added 88.09%
854,796 $0
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $18.2 Million - $22.2 Million
264,452 Added 139.19%
454,450 $31.3 Million
Q2 2021

Aug 16, 2021

SELL
$79.87 - $87.53 $67.8 Million - $74.3 Million
-848,953 Reduced 81.71%
189,998 $0
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $60.5 Million - $80 Million
795,714 Added 327.14%
1,038,951 $84.4 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $12.7 Million - $15.3 Million
156,875 Added 181.65%
243,237 $21.2 Million
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $56.6 Million - $77.1 Million
-896,252 Reduced 91.21%
86,362 $6.32 Million
Q4 2019

Feb 14, 2020

BUY
$73.04 - $95.72 $52.5 Million - $68.8 Million
718,731 Added 272.37%
982,614 $85.8 Million
Q3 2019

Nov 14, 2019

BUY
$72.82 - $86.52 $4.09 Million - $4.85 Million
56,100 Added 27.0%
263,883 $0
Q2 2019

Aug 14, 2019

SELL
$73.52 - $88.7 $21.6 Million - $26.1 Million
-294,030 Reduced 58.59%
207,783 $17.7 Million
Q1 2019

May 15, 2019

SELL
$63.56 - $88.17 $112 Million - $156 Million
-1,768,282 Reduced 77.89%
501,813 $0
Q4 2018

Feb 14, 2019

BUY
$58.5 - $69.94 $38.4 Million - $45.9 Million
656,388 Added 40.68%
2,270,095 $0
Q3 2018

Nov 13, 2018

SELL
$61.75 - $74.23 $16.9 Million - $20.3 Million
-273,493 Reduced 14.49%
1,613,707 $0
Q2 2018

Aug 10, 2018

BUY
$60.85 - $83.98 $76.9 Million - $106 Million
1,264,002 Added 202.83%
1,887,200 $0
Q1 2018

May 11, 2018

BUY
$83.06 - $100.98 $12.8 Million - $15.6 Million
154,494 Added 32.96%
623,198 $51.9 Million
Q4 2017

Feb 09, 2018

SELL
$93.56 - $116.6 $1.21 Million - $1.51 Million
-12,972 Reduced 2.69%
468,704 $44.4 Million
Q3 2017

Nov 09, 2017

BUY
$109.15 - $138.27 $52.6 Million - $66.6 Million
481,676
481,676 $56.2 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $12.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.